source
- STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionThe FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that's sometimes referred to as an "eye stroke."STAT · 9m ago↗ source
- J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reignA Phase 3 trial showed that Johnson & Johnson and Protagonist Therapeutics’ oral therapy Icotyde improved psoriatic arthritis symptoms but AbbVie’s injectable is likely to hold court based on highe…BioSpace · 20m ago↗ source
- Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivalsFull data from the Phase 3 HORIZON trial of Novartis' pelacarsen failed to show any apparent benefit, leading analysts to further reduce the odds of success for Lp(a)-lowering competitors such as A…